Table 1.
Baseline clinical characteristics of all Patients pre- or post-GKRS [%]
| Patient characteristics | Number of patients (%) | Patient characteristics | Number of patients (%) |
|---|---|---|---|
| Sex | KPS | ||
| Female | 58(54.2) | ≥80 | 48(44.9) |
| Male | 49(65.8) | <80 | 59(55.1) |
| Pathological grade | Number of targets | ||
| LGG | 39(36.4) | Single | 45(42.1) |
| HGG | 68(63.6) | Multiple | 62(57.9) |
| Adjuvant treatment after initial surgery | Total volume of targets | ||
| ≥18.5 cm3 | 51(47.7) | ||
| Chemoradiotherapy | 51(47.7) | <18.5 cm3 | 49(52.3) |
| EBRT only | 25(23.4) | Maximum dose | |
| TMZ only | 5(4.7) | ≥24.5 Gy | 54(50.5) |
| GKRS only | 10(9.3) | <24.5 Gy | 53(49.5) |
| None | 16(15.0) | Marginal dose | |
| Age at GKRS procedure | ≥12.5 Gy | 54(50.5) | |
| ≥50 years | 58 (54.2) | <12.5 Gy | 53(49.5) |
| <50 years | 49(45.8) | Two and more GKRS | |
| Recurrence time interval | Yes | 36(33.6) | |
| ≥15 months | 54(50.5) | No | 71(66.4) |
| <15 months | 53(49.5) | Bevacizumab used after recurrence | |
| Surgery for recurrence | Yes | 14(13.1) | |
| Yes | 27(25.2) | No | 93(86.9) |
| No | 80(74.8) |